文献速递糖尿病

索格列净联合胰岛素改善1型糖尿病成人血糖达标时间及血糖变异性:inTandem项目24周动态血糖监测数据汇总分析

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
PubMed 文献 · Diabetes Care · 2019-03-04

该汇总分析基于inTandem1和inTandem2两项双盲随机试验中佩戴盲法动态血糖监测的1型糖尿病成人亚组,比较索格列净200mg、400mg与安慰剂联合优化胰岛素治疗24周的效果。结果显示索格列净显著提高葡萄糖目标范围内时间(TIR),不增加低于3.9 mmol/L的时间,并降低餐后血糖。

要点

  • 索格列净400mg使24周TIR较安慰剂提高11.7%(约2.8小时/天),200mg提高5.4%(约1.3小时/天)。
  • 索格列净200mg和400mg均未增加血糖低于3.9 mmol/L的时间占比。
  • 索格列净200mg和400mg分别降低标准化混合餐后2小时血糖1.9 mmol/L和2.8 mmol/L。

核心结论

  • 在1型糖尿病成人中,索格列净联合优化胰岛素可显著提高葡萄糖TIR且不增加低血糖时间,并降低餐后血糖,从而改善血糖控制。

研究设计与样本

  • 汇总inTandem1(NCT02384941)和inTandem2(NCT02421510)两项双盲随机试验中佩戴盲法CGM的1型糖尿病成人亚组数据。
  • 汇总队列包括安慰剂组93例、索格列净200mg组89例、索格列净400mg组96例。
  • 主要结局为基线至第24周葡萄糖TIR(3.9-10.0 mmol/L)的变化。

主要发现

  • 第24周TIR/低于3.9 mmol/L时间占比:安慰剂组51.6%/5.9%,索格列净200mg组57.8%/5.5%,索格列净400mg组64.2%/5.5%。
  • 安慰剂校正的TIR变化:索格列净200mg为+5.4%(P=0.026;+1.3小时/天),400mg为+11.7%(P<0.001;+2.8小时/天)。
  • 安慰剂校正的低于3.9 mmol/L时间变化:索格列净200mg为-0.3%,400mg为-0.1%。
  • 安慰剂校正的餐后2小时血糖降幅:索格列净200mg为1.9±0.7 mmol/L(35±13 mg/dL;P=0.004),400mg为2.8±0.7 mmol/L(50±13 mg/dL;P<0.001)。

临床怎么用

  • 对于使用优化胰岛素治疗的1型糖尿病成人,可考虑联合索格列净以增加TIR并降低餐后血糖,同时关注其不增加低血糖时间的特点。

局限性

  • 分析基于两项试验中佩戴盲法CGM的亚组人群,非全部随机人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate effects of the dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibitor sotagliflozin in combination with insulin on glucose time in range (TIR) and glucose excursions, postprandial glucose (PPG), and other glycemic metrics in adults with type 1 diabetes using masked continuous glucose monitoring (CGM). RESEARCH DESIGN AND METHODS: Data sets from the inTandem1 (clinical trial reg. no. NCT02384941) and inTandem2 (clinical trial reg. no. NCT02421510) double-blind randomized trials evaluating sotagliflozin versus placebo in adults with type 1 diabetes treated with optimized insulin were pooled for analyses of masked CGM data from a subset of participants in each trial. The pooled cohort included patients randomized to receive placebo (n = 93), sotagliflozin 200 mg (n = 89), or sotagliflozin 400 mg (n = 96). The primary outcome was change from baseline to week 24 in glucose TIR (3.9-10.0 mmol/L [70-180 mg/dL]). Secondary end points included time below and above the target range and 2-h PPG level assessed after a standardized mixed meal. RESULTS: Mean percentage of glucose TIR/percentage time spent at <3.9 mmol/L (<70 mg/dL) during week 24 was 51.6%/5.9%, 57.8%/5.5%, and 64.2%/5.5% with placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg, respectively, which corresponded to a placebo-adjusted change from a baseline of +5.4%/-0.3% (P = 0.026; +1.3/-0.1 h/day) for sotagliflozin 200 mg and +11.7%/-0.1% (P < 0.001; +2.8/-0.02 h/day) for sotagliflozin 400 mg. Placebo-adjusted PPG reductions were 1.9 ± 0.7 mmol/L (35 ± 13 mg/dL; P = 0.004) and 2.8 ± 0.7 mmol/L (50 ± 13 mg/dL; P < 0.001) with sotagliflozin 200 and 400 mg, respectively. CONCLUSIONS: Combined with optimized insulin in type 1 diabetes, sotagliflozin significantly increased glucose TIR without increasing time spent at <3.9 mmol/L and reduced PPG, thereby improving glycemic control.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Danne T, Cariou B, Buse JB, et al. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. Diabetes Care. 2019. PMID: 30833371. doi:10.2337/dc18-2149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。